Core Viewpoint - The merger between ACELYRIN, INC. and Alumis Inc. aims to create a leading clinical-stage biopharma company focused on immune-mediated diseases, enhancing long-term value for stockholders through a diversified late-stage portfolio and strong financial position [1][2]. Company Overview - Alumis is a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases, with a focus on precision approaches to optimize clinical outcomes [7]. - ACELYRIN is dedicated to providing transformative medicines, with its lead program, lonigutamab, targeting thyroid eye disease [8]. Financial Position - As of December 31, 2024, Alumis had approximately $289 million and ACELYRIN had approximately $448 million in cash, cash equivalents, and marketable securities, leading to a pro forma cash position of approximately $737 million for the combined company [6]. - The combined company expects to have sufficient financial resources to support its pipeline and operational needs into 2027 [6]. Pipeline and Development - The merger will result in a diversified portfolio of late-stage clinical assets targeting large markets, including therapies for plaque psoriasis, systemic lupus erythematosus, thyroid eye disease, and multiple sclerosis [6]. - The combined company will benefit from multiple high-value catalysts and a strong management team with a successful track record in developing innovative therapies [2][6]. Transaction Details - The merger is expected to close in the second quarter of 2025, pending stockholder approvals and customary closing conditions [3]. - Alumis plans to file an S-4 registration statement and proxy statement related to the transaction following the completion of fiscal year 2024 audits [4].